Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies


 The use of genomic data to analyze primary endpoints for clinical trials in diffuse large B-cell lymphomas (DLBCL) significantly improved the development of rational drug combinations for genetically defined patient subsets. Recent genetic mouse models and their ability to recapitulate transitions between germinal center exit and memory B-cell characteristics in DLBCL will accelerate the development of rationale-based clinical trials.
 See related article by Flümann et al., (3).
 See related article by Venturutti et al., (5).